EllieMD Reassessment - Design Decisions

1

Info Panel - "In this reassessment, you'll..."

Where it shows: Entry screen (landing) and top of Questionnaire. Sets expectations for what the reassessment involves.

Current default: A (white card with icon and bullet grid)

Not decided

A

Card

White card with teal icon, heading, and a 3-column bullet grid. Restrained, reads as reference material.

B

Teal banner

Solid teal banner with white text. Bolder, more affirmative treatment.

C

Numbered steps

Each bullet becomes a small card with a numbered circle. Scannable, task-list feel.

D

Accordion

Collapsed card with heading only. User clicks to expand the bullets. Minimizes page weight.

Notes (optional)

2

Review Flow - does the Review page stay?

Where it shows: between Selection screen and Questionnaire. The dedicated "Review Your Treatment Plan" page confirms the selection before clinical intake.

Open question from Amir. Any option other than A needs a home for the legal framing and pricing reinforcement currently on the Review page.

Not decided

A

Keep the Review page (current)

Selection → Review page → Questionnaire. Full commitment checkpoint with room for pricing, disclaimers, medical-review note.

Selection → Review → Questions

B

Skip Review entirelyNeeds legal home

Selection → Questionnaire. Fastest flow. Continue button changes to "Continue to Questionnaire."

Selection → Questions

C

Review as modal

Continue opens a confirmation modal on the Selection page with summary, price, and a "Start Questionnaire" CTA. No new page load.

Selection + Modal

D

Expanded summary on Selection pageNeeds legal home

The teal summary bar grows into a fuller zone with price, per-day cost, cycle, and medical-review note. No separate Review page.

Selection (rich) → Questions

E

Review as Step 1 of Questionnaire

Review page stays, but reframes as "Step 1 of 12" with progress bar. Positions confirmation as part of clinical flow, not a separate checkpoint.

Selection → Step 1 → Step 2...

F

Conditional ReviewNeeds legal home

Show Review page only when user actually changed something. Skip for renewals with no changes.

Review if changed

Notes (optional)

3

Base Section - "More Effective" indicator

Where it shows: Base selection section header on the Selection screen. Visually flags that GLP-1/GIP is more effective than GLP-1 alone.

Current default: A (teal ribbon). Option E uses the exact PDF-spec wording "More effective*" as an inline tag.

Not decided

A

Teal ribbon

Solid teal corner ribbon on the recommended base card. Bold, high-contrast.

Most Effective

B

Gold ribbon

Gold corner ribbon. Warmer tone, still prominent.

Most Effective

C

Gold floating chip

Small gold pill floating above the card corner. Less visual weight than a ribbon.

Most Effective

D

Pale teal band

Soft teal-100 band across the top of the card with small text. Calmest treatment.

Most Effective

E

Inline italic "More effective*" (PDF spec)Source text

Exact wording from the Selection Page Edits PDF: the words "More effective*" appear inline next to the base name, in italics. The asterisk links to the clinical footnote.

More effective*

Notes (optional)

4

Base Section - Disclosure pattern

Where it shows: Base cards on the Selection screen. The mechanism behind each pair (how it works, what makes it different) needs somewhere to live.

Current default: A (inline "Read more" expand).

Not decided

A

Inline expand (Read more)

Small "Read more" link under description; click to reveal mechanism copy inline.

B

Mechanism tags

Small pill tags summarize mechanism at a glance (e.g., "Appetite regulation", "Glucose control"). No hidden content.

C

Drawer / side panel

"Learn more" button opens a side drawer with the full mechanism explanation.

D

Accordion

Each base card has an accordion chevron that expands the full mechanism block within the card.

E

Comparison table

Dedicated compare view showing both bases side by side with mechanism, effectiveness, pricing rows.

F

Compare button

Single "Compare bases" button at the section bottom that opens an on-demand comparison modal.

Notes (optional)

5

Additive Section - Presentation

Where it shows: Additive selection section on the Selection screen. How users explore and pick an additive (NAD+, B12, Glycine, L-Carnitine, or None).

Option G is the PDF spec (Most Popular chip + chevron). Other options were divergent explorations.

Not decided

A

Tags visible (current)

Each additive card shows benefit tags (e.g., "Energy", "Recovery") inline below the name.

B

Goal filter

Filter chips at the top of the section (Energy, Mood, Recovery) that highlight which additives match each goal.

C

Compare button

"Compare additives" button opens a comparison table across all options.

D

Icon-forward

Large icons (lightning, brain, muscle) lead each card, with descriptions secondary.

E

Quiz

A mini quiz ("What's your goal?") narrows down to a recommended additive.

F

Strength meters

Each additive shows bar-style meters rating it on Energy, Mood, Recovery.

G

PDF spec - Most Popular chip + chevronSource doc

NAD+ tagged "Most Popular"; each card has a functional chevron to expand full description. Matches the Selection Page Edits PDF spec.

Notes (optional)

6

Dose Section - Display pattern

Where it shows: Dose selection section on the Selection screen (WL injection only). How users see their current dose and choose to maintain / increase / decrease.

Source-approved tiers and mg amounts in all variants. Differences are presentation only.

Not decided

A

Refined trio

Three color-coded cards (Decrease / Maintain / Increase) with arrow pills and serif mg amounts. Restrained, equal visual weight.

B

Dose ladder

Vertical ladder showing all dose levels in mg. "You are here" pin marks the current dose. Available next steps are selectable.

C

Comparison table

Table with columns for each option (mg, direction, note). More data-dense.

D

Delta-focused rows

Row per available transition. Anchors on the current state; emphasizes the change rather than the destination.

E

Spectrum slider

Horizontal slider with snap-to-tick behavior. Drag or keyboard to pick dose along a spectrum from lowest to highest.

F

Hero + alternates

Large recommended-dose card up top, alternates below as secondary options.

Notes (optional)

7

BMI Eligibility - Display on Weight Management option

Where it shows: Program section on the Selection screen when a Microdose user is considering switching to Weight Management (requires BMI 22+).

Needs to clearly tie the BMI requirement to the WM option specifically, not MD. Source copy: "Requires a BMI of 22 or higher."

Not decided

A

Eligibility footer inside card

Gold footer section at the bottom of the WM card with "Eligibility" pill + full requirement sentence. Contained within the card border.

B

Inline requirement pillCopy compressed

Compact gold pill "BMI 22+ required" next to the Weight Management title. Fast to scan but uses compressed wording (not verbatim source).

C

Requirement row inside card

Gray-bg row below description with check icon: "Eligibility: Requires a BMI of 22 or higher."

D

Pointer callout below card

Gold callout with an upward-pointing arrow tip, attached visually to the WM card.

E

Corner badge + inline line

"Eligibility" pill in the card corner + a gold inline line below the description with the requirement sentence.

Notes (optional)

8

Clinical Footnote - "Based on clinical studies" disclaimer

Where it shows: Below the Base selection section. Ties back to the "More effective*" tag and explains the clinical evidence basis.

Source copy is fixed; this is purely about presentation. The asterisk reference system is active only when Decision 3 is option E.

Not decided

A

Italic asterisk footnote

Small italic text with leading asterisk, placed directly below the base section. Classic footnote treatment.

B

Gold star icon + bold inline

Gold star icon replacing the asterisk; first few words of the note in semibold to draw the eye.

C

Teal callout box

Framed teal-100 box with the footnote copy. Visually elevated compared to a footnote.

D

Serif italic footnote (with *)

Small serif italic copy with a gold asterisk prefix. Feels editorial.

E

"Why 'more effective'?" trigger

A small question trigger that reveals the full footnote on click. Progressive disclosure.

F

Muted footnote with gold *

Ink-300 muted footnote with gold asterisk prefix. Quietest presentation.

Notes (optional)

9

Medical Disclaimer - "Final treatment decisions are made by a licensed provider"

Where it shows: Bottom of the Selection screen, just above the fold under the summary bar. Sets expectations that the provider has final say.

Source copy: "Final treatment decisions, including dosing and formulation, are determined by a licensed provider based on your individual health profile."

Not decided

A

Plain centered italic

Simple centered italic text. Low visual weight, doesn't compete with CTAs.

B

Gray-bg icon row

Stethoscope icon + copy on a neutral gray row. Iconography signals "medical."

C

Neutral callout

Framed neutral callout box with shield icon. More formal feel.

D

Centered serif italic

Lora italic centered text, no icon or marker. Quietly editorial.

E

"How are treatment decisions made?" trigger

Question trigger that expands to reveal the full disclaimer. Progressive disclosure.

F

Trust panel

Panel with a verification seal graphic and the line "A licensed provider reviews every change." Most reassuring, heaviest presentation.

Notes (optional)

Pending Copy Approvals

Content items waiting on your signoff, separate from the presentation decisions above. For each, pick one: Approve as-is, Needs changes (write what in notes), or Needs more info.

Info Panel bulletsProposed copy

The three bullets under "In this reassessment, you'll":
• Share any updates to your medical history since last intake
• Let your provider know how your treatment has been working
• Review, consent, and verify your ID before provider sign-off

Approve as-isNeeds changesNeeds more info

Additive descriptions (B12, Glycine, L-Carnitine)From source tab

Descriptions pulled verbatim from the Frontend Tier Display tab. Wording for each additive currently shipping in the prototype:
• B12: "Vitamin B12 is a nutrient that supports energy metabolism and nervous system function."
• Glycine: (current copy in prototype)
• L-Carnitine: (current copy in prototype)

Approve as-isNeeds changesNeeds more info

Disqualification screen heading

The H1 users see when they're disqualified mid-questionnaire. Currently: "We need to pause your reassessment." Is this the final wording?

Approve as-isNeeds changesNeeds more info

Confirmation screen chrome

Post-submission confirmation screen framing: heading, subhead, illustration or icon treatment. The prototype's current version flagged [Pending Stephanie Approval].

Approve as-isNeeds changesNeeds more info

GLP-1 + GIP vs GLP-1/GIP formatting

The compound base is displayed two different ways in source materials: as GLP-1 + GIP (plus format) or GLP-1/GIP (slash format). Which should ship?

Use GLP-1 + GIPUse GLP-1/GIPNeeds more info

"84-day commitment" placement

Where should the 84-day treatment commitment note live? Options currently explored: on each base card, in the summary bar, on the Review page, or in the questionnaire.

Program option descriptionsNot in source

Short descriptions used under each program name in the Program selection section. Not in any source doc - proposed copy:
• Microdose: "Longevity-focused low-dose maintenance."
• Weight Management: "Active weight-loss treatment at standard dosing."

Approve as-isNeeds changesNeeds more info

Program Switch screen copyPending Lauren too

Shown when a Microdose patient changes Program to Weight Management on Selection and hits Continue. Handles the transition moment before routing to a new intake. Current proposed body copy: "Weight Management uses a different starting dose than Microdose. A new medical intake is required so a licensed provider can determine your starting dose before prescribing." Separately blocked by Lauren on: what happens to the patient's current Microdose subscription (auto-pause, auto-continue, billing cutover) during the switch.

Approve as-isNeeds changesNeeds more info

GLP-1/GIP source description typoFYI

Heads up: the Frontend Tier Display tab's GLP-1/GIP description contains an appended typo fragment. Source reads: "Targets two complementary hormone pathways involved in appetite and blood sugar regulation.involved in appetite and blood sugar control." The prototype uses the clean version ("...involved in appetite and blood sugar regulation.") - Lauren should confirm this is OK or specify the correct ending.

Clean version is correctProvide corrected versionFlag to Lauren

Final Design Decisions

for Stephanie's review and signoff

How to use this document

Info Panel - "In this reassessment, you'll..."

Review Flow - does the Review page stay?

Base Section - "More Effective" indicator

Base Section - Disclosure pattern

Additive Section - Presentation

Dose Section - Display pattern

BMI Eligibility - Display on Weight Management option

Clinical Footnote - "Based on clinical studies" disclaimer

Medical Disclaimer - "Final treatment decisions are made by a licensed provider"

Pending Copy Approvals

Signoff